Latest Earnings Results: Q2 '26
Estimated EPS
$0.00
Reported EPS
$0.00
Surprise
+100%
Estimated Rev
$0.5M
Reported Rev
$0.29M
Surprise
-41.2%
• Reported GAAP EPS of $0.00 • Reported revenue of $0.29M down -3.33% YoY • BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.
Bullish Takeaway
BioLineRx advanced GLIX1 Phase 1/2a glioblastoma clinical dosing, demonstrated preclinical synergy in ovarian cancer to enable trial expansion and collaboration discussions, while maintaining cash runway guidance into the first half of 2027.
Bearish Takeaway
BioLineRx reported an increased net loss of $4.3M, rising research and administrative operating expenses, ongoing dilution from a $3.75M offering, and regional operational uncertainties stemming from the security situation in Israel.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.38 | -- | -- | N/A |
Q2 '26 | $0.00 | $0.00 | 100.00% | EXPECTED |
Q1 '26 | -$1.04 | $0.00 | 100.00% | BEAT |
Q4 '25 | -$0.38 | -- | -- | N/A |
Q3 '25 | -$0.67 | $0.00 | 100.00% | BEAT |